2025
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or CAR T- cell therapy: An ASTCT Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines
Munshi P, Olin R, Wall S, McCurdy S, Al-Juhaishi T, Baker J, Bhatt V, Chokr N, Dahi P, DeFilipp Z, Espinoza-Gutarra M, Farhan S, Gowda L, Hamilton B, Inamoto Y, Jayani R, Kharfan-Dabaja M, Lin R, Meyers G, Mishra A, Murthy H, Nawas M, Rosko A, Ruiz M, Sorror M, Sung A, Carpenter P, Hamadani M, Artz A. US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or CAR T- cell therapy: An ASTCT Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines. Transplantation And Cellular Therapy 2025 PMID: 39961473, DOI: 10.1016/j.jtct.2025.02.014.Peer-Reviewed Original ResearchHematopoietic cell transplantationT-cell therapyCAR-T cell therapyCAR-TCell transplantationGeriatric assessmentCellular therapyChimeric antigen T-cell therapyAmerican Society for TransplantationPromote risk stratificationAllo-HCTRisk stratificationCell therapyOlder patientsRoutine GAOlder adultsGa uptakeTherapyPhysician practice patternsTransplantationPractice patternsClinical support staffCross-sectional surveyPhysician membersDomain of GA
2023
Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Sidana S, Ahmed N, Akhtar O, Heim M, Brazauskas R, Hansen D, Ferreri C, Freeman C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison M, Kitali A, Mirza S, Patel J, Patwardhan P, Usmani S, Patel K, Ganguly S, Pasquini M. Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma. Blood 2023, 142: 1027. DOI: 10.1182/blood-2023-181762.Peer-Reviewed Original ResearchCAR T-cell therapyRefractory multiple myelomaCytokine release syndromeHigh-risk cytogeneticsProgression-free survivalLow performance statusReal-world populationExtramedullary diseasePerformance statusClinical trialsResponse rateCell therapyMultivariate analysisOverall survivalMedian timeMultiple myelomaRelapsed/Refractory Multiple MyelomaTreatment of RRMMCAR T-cell doseISS stage III diseasePresence of EMDGood partial response rateLarge real-world studyPre-treated populationComplete response rate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply